Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2007-06-19
2010-06-08
Carlson, Karen Cochrane (Department: 1657)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Reexamination Certificate
active
07731938
ABSTRACT:
The present invention relates to the assessment of colorectal cancer. It discloses the use of the CYFRA 21-1 assay in the assessment of colorectal cancer. It also relates to a method for assessing colorectal cancer in vitro using a liquid sample, derived from an individual by measuring CYFRA 21-1 in said sample. Measurement of CYFRA 21-1 can, e.g., be used in the early detection or in the follow-up of patients with colorectal cancer.
REFERENCES:
patent: 2004/0038225 (2004-02-01), Markowitz
patent: 1439393 (2004-07-01), None
patent: 2004/057336 (2004-07-01), None
patent: 2004/104593 (2004-12-01), None
Yeh et al, “Monitoring Cytokeratin Fragment 10 (CYFRA 21-1) Serum Levels for Early Prediction of Recurrence of Adenocarcinoma and Squamous Cell Carcinom in the Lung after Surgical Resection,” (Lung), 2002, vol. 180, pp. 273-279.
Kashihara et al, “Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level,” (J. Gastroenterol) 1998, vol. 33, pp. 447-453.
Bernick et al, “Neuroendocrine Carcinomas of the Colon and Rectum,” (Dis of the Colon and Rectum), 2004, vol. 47, pp. 163-169.
Molina et al. “Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases”, Tumor Biol., 1994, 15:318-325.
Ahlquist, D., “Fecal Occult Blood Testing for Colorectal Cancer,” Colorectal Neoplasia, Part II, 26;1 (Mar. 1997) 41/55.
Bodenmuller, H. et al., “Lung Cancer-Associated Keratin 19 Fragments: Development and Biochemical Characterisation of the New Serum Assay Enzymun-Test CYFRA 21-1,” The International Journal of Biological Markers, 9;2 (1994) 75-81.
Duffy, M. et al., “Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines,” European Journal of Cancer, 39 (2003) 718-727.
Ebert, W. et al., “Cytokeratin 19 Fragment CYFRA 21-1 Compared with Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen and Neuron-Specific Enolase in Lung Cancer,” Eur. J. Clin. Chem. Clin. Biochem, 32 (1994) 189-199.
Hoffmann, D. et al., “The Prognostic Value of CEA, CA242, CA19-9, CA72-4, CYFRA 21-1 and S100 in Colorectal Cancer,” Tumor Biol, 24 (2003) 49-Abstract P-14 CEA.
Kojima, O. et al., “Tumor Marker, Serological Detection of Cancer,” Rinsho Byori. Jap. Clin. Pathol. 34 (2004) 337-339.
Lamerz, R., Clinical Laboratory Diagnostics: Use and Assessment of Clinical Laboratory Results, First Edition, TH-Books Verlagsgesellschaft mbH, Frankfurt/Main, Germany.
Martell, R.E. et al., “OVX1 and CEA in Patients with Colon Carcinoma, Colon Polyps and Benign Colon Disorders,” The International Journal of Biological Markers, 13;3 (1998) 145-149.
Matsumoto, H., Journal of Japan Society of Coloproctology, 55 (2002) 136-144.
Matsumoto, H., Database Biosci, Info. Servc. Philadelphia (2002)—Database accession No. PREV200200296087-XP002329221.
Miyashita, T. et al., Database Biosci, Info. Servc. Philadelphia (2002)—Database accession No. PREV200000195119-XP002329220.
Miyashita, T. et al., Journal of Japan Society of Coloproctology,53 (2000)76-82.
Nakata, B. et al., “Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer,” British Journal of Cancer, 91 (2004) 873-878.
Qiang, Z. et a., “Diagnostics Value of Multi-Tumor Markers Protein Biochip Detective System for Digestive Tract Cancer,” Zhongguo Zhongliu Linchaung, 31 (2004) 337-339.
Sakahara, H. et al., Kakuigaku, 30 (1993) 1475-1479.
Sturgeon, C., “Practice Guidelines for Tumor Marker Use in the Clinic,” Clinical Chemistry, 48:8 (2002) 1151-1159.
Van Der Gaast, A. et al., “Evaluation of a New Tumour Marker in Patients with Non-Small-Cell Lung Cancer: Cyfra 21.1,” Br. J. Cancer, 69 (1994) 525-528.
Vaughn, C. et al., “Ferritin, A Potential Marker for Cancer of the Colon,” Proc. Am. Assoc. Cancer Res. Annual Meeting, 30 (19989) 26-Abstract No. 101.
Yokoyama, T. et a., “Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer,” Cancer Letters, 202 (2003) 101-108.
Zweig, M. et al., “Receiver-Operating Characteristic (ROC) Plots: A fundamental Evaluation Tool in Clinical Medicine,” Clin. Chem., 39;4 (1993) 561-577.
Andres Herbert
Grunert Veit Peter
Karl Johann
Rollinger Wolfgang
Zolg Werner
Amick Marilyn
Carlson Karen Cochrane
Roche Diagnostics Operations Inc.
Shen Bin
LandOfFree
CYFRA 21-1 as a marker for colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CYFRA 21-1 as a marker for colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CYFRA 21-1 as a marker for colorectal cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189005